US-based surgical software and automation technology provider Caresyntax completed a $100m series C round yesterday featuring semiconductor technology producer Intel, healthcare services provider Optum, insurer Relyens and conglomerate Rezayat Group.
The round was led by investment manager PFM Health Sciences and included asset manager Lauxera Capital Partners, life science-focused fund Vesalius Biocapital III, credit fund Arno Capital, venture capital fund Surgical.AI and alternative finance provider IPF Partners.
Intel, Optum and Rezayat Group, were represented by their respective corporate venturing subsidiaries: Intel Capital, Optum Ventures and Rezayat Investments.
Caresyntax provides a software platform that utilises artificial intelligence (AI) technology and data analytics to assist medical professionals in surgeries. Its software is used in more than 4,000 operating rooms globally and has supported the work of more than 30,000 surgeons.
The funding will support plans to continue the company’s expansion in key markets and the development of its AI-enabled analytics technology and software platforms.
Norgine Ventures, a corporate venturing subsidiary of pharmaceutical firm Norgine, invested $11.9m in Caresyntax in 2017 prior to a $20m capital injection from Surgical.AI the following year.
The company secured $45.6m in a late 2019 round backed by Reylens, diversified conglomerate Mitsubishi Corporation and healthcare imaging technology provider Barco Healthcare.
Drug Discovery Gateway, a joint investment fund formed by pharmaceutical firm Takeda and alternative asset manager Whiz Partners, also took part in that round, as did Plug and Play, IPF Partners and Caresyntax’s founders.